ZeeCRO Sells Bioanalytical Division

Tuesday, December 29, 2009 07:42 AM

Cary, N.C.-based contract research organization (CRO) ZeeCRO, formerly AAIPharma Services, sold its bioanalytical division to Kansas Venture Capital, Inc., (KVCI) for an undisclosed sum. KCVI plans to grow the bioanalytical business, which is now a new company, KCAS, Inc.

ZeeCRO streamlined operations to focus on its CRO business in October by selling off its pharmaceutical development services business. As part of that sale, the company lost the rights to the AAIPharma name.  According to ZeeCRO’s web site, the CRO continues to offer early- and late-stage development services to global customers. 

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs